Tag: clinical studies
-
Revive Therapeutics (RVV.C) finds $23 million and throws it at their bucillamine clinical studies
Revive Therapeutics (RVV.C) provided an update on their Phase 3 clinical trial for bucillamine for COVID-19 today. Primarily, the update’s about funding and more specifically their recent $23 million financing. The company intends to use the monies to fund their aggressive expansion from14 clinical sites to 50 to meet their enrolment requires for the study…